July 23 (Reuters) - AstraZeneca Plc said on Friday
its diabetes drug Bydureon was approved in the United States for
use in patients as young as age 10 to help reduce blood sugar
levels along with diet and exercise.
The drug, chemically called exenatide, is an injectable
suspension taken once a week for 10-to 18-year olds who have
type-2 diabetes, the most common form of the condition where the
body does not produce enough of the sugar-checking hormone,
insulin.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Bernard
Orr)